Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Nguyen AnhCoPresident and CEO | Atara BiotherapeuticsATRA | Open-market sale | 05/18 | 05/20 | 5,241 sh | $9.13 | $47,850.33 | −3.7% |
Yanina Grant-HuertaChief Accounting Officer | Atara BiotherapeuticsATRA | Open-market sale | 05/18 | 05/20 | 2,414 sh | $9.13 | $22,039.82 | −4.6% |
James HuangDirector | Atara BiotherapeuticsATRA | Open-market sale | 05/07 | 05/11 | 313,446 sh | $10.10 | $3,165,804.6 | −23.7% |
EcoR1 Capital10% Owner | Atara BiotherapeuticsATRA | Open-market buy | 05/07 | 05/11 | 507,407 sh | $9.35 | $4,744,255.45 | +48.6% |
Panacea Innovation10% Owner | Atara BiotherapeuticsATRA | Open-market sale | 05/07 | 05/11 | 313,446 sh | $10.10 | $3,165,804.6 | −23.7% |
President and CEO | Atara BiotherapeuticsATRA | Open-market sale | 03/02 | 03/04 | 2,996 sh4 trades | $5.09avg. | $15,247.08 | −4.6% |
Atara BiotherapeuticsATRA | Open-market sale | 03/02 | 03/04 | 2,104 sh4 trades | $5.08avg. | $10,688.32 | −6.2% | |
James HuangDirector | Atara BiotherapeuticsATRA | Open-market sale | 01/12 | 01/14 | 80,554 sh | $6.07 | $488,962.78 | −5.7% |
Panacea Innovation10% Owner | Atara BiotherapeuticsATRA | Open-market sale | 01/12 | 01/14 | 80,554 sh | $6.07 | $488,962.78 | −5.7% |
President and CEO | Atara BiotherapeuticsATRA | Open-market sale | 25/11/17 | 25/11/19 | 2,915 sh2 trades | $13.19avg. | $38,448.85 | −4.3% |
Atara BiotherapeuticsATRA | Open-market sale | 25/11/17 | 25/11/19 | 1,804 sh3 trades | $13.19avg. | $23,794.76 | −5.1% | |
President and CEO | Atara BiotherapeuticsATRA | Open-market sale | 25/08/18 | 25/08/20 | 2,958 sh3 trades | $11.62avg. | $34,371.39 | −4.2% |
Atara BiotherapeuticsATRA | Open-market sale | 25/08/18 | 25/08/20 | 1,809 sh3 trades | $11.61avg. | $21,002.49 | −4.9% | |
James HuangDirector | Atara BiotherapeuticsATRA | Open-market buy | 25/08/15 | 25/08/19 | 55,000 sh | $12.19 | $670,450 | +4.1% |
Panacea Innovation10% Owner | Atara BiotherapeuticsATRA | Open-market buy | 25/08/15 | 25/08/19 | 55,000 sh | $12.19 | $670,450 | +4.1% |
James HuangDirector | Atara BiotherapeuticsATRA | Open-market buy | 25/07/17 | 25/07/21 | 19,335 sh | $9.64 | $186,389.4 | +1.5% |
Panacea Innovation10% Owner | Atara BiotherapeuticsATRA | Open-market buy | 25/07/17 | 25/07/21 | 19,335 sh | $9.64 | $186,389.4 | +1.5% |
Nguyen AnhCoPresident and CEO | Atara BiotherapeuticsATRA | Open-market sale | 25/05/16 | 25/05/20 | 3,276 sh | $6.76 | $22,145.76 | −4.4% |
Yanina Grant-HuertaChief Accounting Officer | Atara BiotherapeuticsATRA | Open-market sale | 25/05/16 | 25/05/20 | 2,218 sh | $6.76 | $14,993.68 | −5.6% |
Hyllengren Eric J.EVP, CFO and COO | Atara BiotherapeuticsATRA | Open-market sale | 25/03/03 | 25/03/05 | 1,211 sh | $7.00 | $8,477 | −2.1% |
